CLYM

$0.00

(

+0.00%

)
Quote details

stock

Climb Bio Inc

NASDAQ | CLYM

2.30

USD

+$0.00

(

+0.00%

)

At Close (As of Dec 11, 2025)

$141.82M

Market Cap

-

P/E Ratio

-0.59

EPS

$2.90

52 Week High

$1.05

52 Week Low

HEALTHCARE

Sector

CLYM Chart

Recent Chart
Price Action

CLYM Technicals

Tags:

CLYM Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$82M
Selling General And Administrative $16M
Research And Development $14M
Operating Expenses $82M
Investment Income Net -
Net Interest Income $8.1M
Interest Income $8.1M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -
Income Before Tax -$74M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$74M
Comprehensive Income Net Of Tax -
Ebit -$82M
Ebitda -$30M
Net Income -$74M

Revenue & Profitability

Earnings Performance

CLYM Financials

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$82M
Selling General And Administrative $16M
Research And Development $14M
Operating Expenses $82M
Investment Income Net -
Net Interest Income $8.1M
Interest Income $8.1M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -
Income Before Tax -$74M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$74M
Comprehensive Income Net Of Tax -
Ebit -$82M
Ebitda -$30M
Net Income -$74M

CLYM News

CLYM Profile

Climb Bio Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Climb Bio, Inc. is a biotechnology company based in Wilmington, Delaware, specializing in the development of innovative therapies for autoimmune-driven inflammatory diseases. With a strong and diverse pipeline of drug candidates, Climb Bio harnesses advanced scientific research to address significant unmet medical needs in this therapeutic area. The company’s strategic focus on research and development, combined with its commitment to enhancing patient outcomes, establishes Climb Bio as a vital entity within the biotechnology field, poised for potential growth and impact in the industry.

ATPC
+164.70%
$0.18
LPTX
+368.57%
$2.05
NVDA
-1.55%
$180.93
WOK
-11.52%
$0.16
PAVS
-9.21%
$0.03
VSME
+11.42%
$0.09
PETS
+68.36%
$2.98
RZLT
-87.20%
$1.40
YGMZ
-61.42%
$0.02
PLUG
+4.42%
$2.36
ORCL
-10.83%
$198.85
RIVN
-6.11%
$16.43
ASST
-7.82%
$0.92
VIVK
+14.55%
$0.07
URG
-8.08%
$1.25
KIND
+9.48%
$2.77
NXDR
+9.48%
$2.77
AXDX
-61.36%
$0.03
IVP
-12.52%
$0.05
ONDS
+8.34%
$9.02
IRBT
-4.58%
$5.00
INTC
-3.11%
$39.51
F
+1.64%
$13.63
MIGI
-8.95%
$6.10
TSLA
-1.01%
$446.89
KVUE
0.00%
$17.32
BTTC
+24.28%
$4.12
ADAP
-15.14%
$0.05
DNN
+2.60%
$2.76
AAL
-1.18%
$14.96
AVGO
-1.59%
$406.37
HOOD
-9.05%
$123.38
MARA
-0.67%
$11.84
NFLX
+1.48%
$94.09
TE
-4.55%
$5.87
K
-0.01%
$83.44
SOND
-23.45%
$0.12
GOOGL
-2.42%
$312.43
SOFI
-0.07%
$27.07
BMNR
-5.00%
$38.38
WBD
-0.13%
$29.49
BTG
0.00%
$4.68
RR
+12.77%
$4.68
VALE
+2.30%
$13.29
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
T
-0.36%
$24.30
RGTI
+2.90%
$26.88
BYND
-4.06%
$1.18
ADD
-25.47%
$0.05
NIO
+1.98%
$5.13
PLTR
-0.19%
$187.54
BAC
+0.88%
$54.56
SRM
+53.27%
$10.30
PFE
+0.07%
$25.80
HL
+12.56%
$19.35
ASBP
+22.50%
$0.10
PLTD
+0.15%
$6.32
AAPL
-0.26%
$278.03
GRAB
0.00%
$5.18
BITF
0.00%
$2.94
HPE
-2.85%
$24.54
RIG
-0.46%
$4.28
RKLB
+10.44%
$63.53
JBLU
-2.78%
$4.89
QBTS
+4.40%
$27.98
AMD
+0.00%
$221.43
BMNU
-10.03%
$10.22
CIFR
+2.16%
$18.88
NGD
+9.19%
$8.55
ACHR
+2.27%
$8.56
AG
+7.13%
$16.81
CDE
+9.45%
$17.48
AMZN
-0.64%
$230.28
MTSR
-0.35%
$70.50
BBD
+2.71%
$3.41
BTBT
+4.23%
$2.46
SNAP
-3.53%
$7.64
CRWV
-0.88%
$87.38
IREN
+0.04%
$43.94
NCLH
+6.80%
$20.55
ABEV
+2.04%
$2.50
FI
+2.38%
$68.16
GOOG
-2.27%
$313.70
NOK
+2.25%
$6.36
MSFT
+1.02%
$483.47
HBAN
+1.99%
$17.91
CCL
+5.93%
$27.84
PCG
-1.65%
$14.83
AFMD
-34.94%
$0.18
KO
-1.56%
$69.11
SMCI
-2.52%
$34.02
WULF
+0.44%
$15.83
LUV
+2.28%
$40.74
UBER
+1.52%
$85.44
CNQ
-1.72%
$33.14
SOUN
-1.47%
$12.03
SMR
+4.42%
$21.22
CHR
-5.72%
$0.04
CLSK
+1.99%
$14.82
ATPC
+164.70%
$0.18
LPTX
+368.57%
$2.05
NVDA
-1.55%
$180.93
WOK
-11.52%
$0.16
PAVS
-9.21%
$0.03
VSME
+11.42%
$0.09
PETS
+68.36%
$2.98
RZLT
-87.20%
$1.40
YGMZ
-61.42%
$0.02
PLUG
+4.42%
$2.36
ORCL
-10.83%
$198.85
RIVN
-6.11%
$16.43
ASST
-7.82%
$0.92
VIVK
+14.55%
$0.07
URG
-8.08%
$1.25
KIND
+9.48%
$2.77
NXDR
+9.48%
$2.77
AXDX
-61.36%
$0.03
IVP
-12.52%
$0.05
ONDS
+8.34%
$9.02
IRBT
-4.58%
$5.00
INTC
-3.11%
$39.51
F
+1.64%
$13.63
MIGI
-8.95%
$6.10
TSLA
-1.01%
$446.89
KVUE
0.00%
$17.32
BTTC
+24.28%
$4.12
ADAP
-15.14%
$0.05
DNN
+2.60%
$2.76
AAL
-1.18%
$14.96
AVGO
-1.59%
$406.37
HOOD
-9.05%
$123.38
MARA
-0.67%
$11.84
NFLX
+1.48%
$94.09
TE
-4.55%
$5.87
K
-0.01%
$83.44
SOND
-23.45%
$0.12
GOOGL
-2.42%
$312.43
SOFI
-0.07%
$27.07
BMNR
-5.00%
$38.38
WBD
-0.13%
$29.49
BTG
0.00%
$4.68
RR
+12.77%
$4.68
VALE
+2.30%
$13.29
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
T
-0.36%
$24.30
RGTI
+2.90%
$26.88
BYND
-4.06%
$1.18
ADD
-25.47%
$0.05
NIO
+1.98%
$5.13
PLTR
-0.19%
$187.54
BAC
+0.88%
$54.56
SRM
+53.27%
$10.30
PFE
+0.07%
$25.80
HL
+12.56%
$19.35
ASBP
+22.50%
$0.10
PLTD
+0.15%
$6.32
AAPL
-0.26%
$278.03
GRAB
0.00%
$5.18
BITF
0.00%
$2.94
HPE
-2.85%
$24.54
RIG
-0.46%
$4.28
RKLB
+10.44%
$63.53
JBLU
-2.78%
$4.89
QBTS
+4.40%
$27.98
AMD
+0.00%
$221.43
BMNU
-10.03%
$10.22
CIFR
+2.16%
$18.88
NGD
+9.19%
$8.55
ACHR
+2.27%
$8.56
AG
+7.13%
$16.81
CDE
+9.45%
$17.48
AMZN
-0.64%
$230.28
MTSR
-0.35%
$70.50
BBD
+2.71%
$3.41
BTBT
+4.23%
$2.46
SNAP
-3.53%
$7.64
CRWV
-0.88%
$87.38
IREN
+0.04%
$43.94
NCLH
+6.80%
$20.55
ABEV
+2.04%
$2.50
FI
+2.38%
$68.16
GOOG
-2.27%
$313.70
NOK
+2.25%
$6.36
MSFT
+1.02%
$483.47
HBAN
+1.99%
$17.91
CCL
+5.93%
$27.84
PCG
-1.65%
$14.83
AFMD
-34.94%
$0.18
KO
-1.56%
$69.11
SMCI
-2.52%
$34.02
WULF
+0.44%
$15.83
LUV
+2.28%
$40.74
UBER
+1.52%
$85.44
CNQ
-1.72%
$33.14
SOUN
-1.47%
$12.03
SMR
+4.42%
$21.22
CHR
-5.72%
$0.04
CLSK
+1.99%
$14.82

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.